Antibodies

17 Jul 2018 Eureka Therapeutics Announces that Boehringer Ingelheim is Exercising an Option to License Novel TCR Mimic (TCRm) Antibodies
13 Jul 2018 Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
13 Jul 2018 CStone's PD-1 inhibitor CS1003 receives clinical trial approval in China
13 Jul 2018 Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
13 Jul 2018 Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA
12 Jul 2018 FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
11 Jul 2018 MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn's Disease
11 Jul 2018 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Hepatocellular Carcinoma
11 Jul 2018 Bristol-Myers Squibb’s Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and Irinotecan
10 Jul 2018 Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
10 Jul 2018 Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia
10 Jul 2018 JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Rituximab Biosimilar
06 Jul 2018 JHL Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma
06 Jul 2018 Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months
03 Jul 2018 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy as First-Line Treatment for Metastatic Squamous Non-Small Cell Lung Cancer
03 Jul 2018 New studies confirm anti-CD160 antibodies are potential therapeutics for ophthalmic diseases
03 Jul 2018 Aslan Pharmaceuticals submits clinical trial authorisation application for first in man studies for ASLAN004
02 Jul 2018 Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
01 Jul 2018 HuMax®-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics
29 Jun 2018 Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma
29 Jun 2018 Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes
29 Jun 2018 CHMP recommends approval of Cablivi(TM) (caplacizumab)
29 Jun 2018 Prestige Biopharma and Alvogen Announce License and Supply Agreement to Commercialize Prestige´s Trastuzumab Biosimilar (Hervelous™) in Central and Eastern Europe
28 Jun 2018 Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
28 Jun 2018 BioAtla Announces First Patient Treated In Phase1/2 BA3021-001 Clinical Trial For CAB-ROR2-ADC Therapeutic

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top